APLLTD Alembic Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall
Alembic Pharma delivered a steady Q1 FY26, characterized by double-digit growth in international markets which offset a sluggish performance in the domestic branded segment. The company is benefiting from improved gross margins (76.2%) and operating leverage as new facilities ramp up. Management is focused on resolving execution issues in India and scaling the US injectable and complex generic pipeline to sustain growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 1,580 | 1,406 | 1,571 | 1,494 |
| EBITDA | 259 | 180 | 171 | 214 |
| Net profit | 166 | 86 | 75 | 104 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
